MedTrace Logo

Magnesium and Dexmedetomidine in Pheochromocytoma

NCT05102058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2021-11-01

No results posted yet for this study

Summary

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Conditions

  • Phaeochromocytoma Crisis
  • Hemodynamic Instability

Interventions

DRUG

Magnesium-Dexmedetomidine

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Nükhet Sivrikoz, MD · Attending anesthesiologist

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2020-03-01
Completion
2020-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05102058 on ClinicalTrials.gov